How much does a bottle of gilitinib cost in China?

Giritinib is a drug that has shown excellent efficacy in the treatment of relapsed or refractory acute myeloid leukemia. As an AXL receptor tyrosine kinase inhibitor, it provides a new treatment option for patients with this type of leukemia. However, although this drug has been launched in the domestic market, it has not been included in the medical insurance system, so patients who need to receive this drug must bear the high cost themselves.

Take the domestically imported version of giritinib as an example. Each box contains 21 tablets, each 40mg. The current price on the market is as high as 25,000 to 6,000 yuan, which is undoubtedly a heavy burden for ordinary patients. If patients consider purchasing the overseas version, the price is even more staggering. The price of the Hong Kong version of the drug is about 9 yuan per box of 42 tablets, while the price of the European version of 84 tablets is as high as 21 yuan, which is undoubtedly an astronomical figure for many patients.

Fortunately, in Laos, some pharmaceutical companies such as ASEAN Pharmaceuticals, Daxiong Pharmaceuticals and Lucius Pharmaceuticals have successfully developed generic versions of giritinib and have successfully launched them on the market. These generic drugs come in different specifications, including 28 tablets, 84 tablets, and 90 tablets, etc. With the same packaging, the price is far lower than that of the original drug, only between 2000 and 5000 yuan. This undoubtedly provides patients with a more economical treatment path.

However, patients must be cautious when choosing to purchase, and must purchase through formal and legal channels to ensure that the drugs they purchase are of high quality, thus providing a solid guarantee for their health and safety. You must not choose illegal channels just for the sake of cheap, so as not to buy fake and inferior drugs and cause greater harm to your body.

After multiple rigorous clinical trials, giltinib has demonstrated significant efficacy in the treatment of FLT3 mutated AML patients. Whether used as monotherapy or in combination with other chemotherapy drugs, giltinib effectively improved patients' conditions and extended their survival.